Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas

Clinical Nuclear Medicine

Volumn 34, Issue 12, 2009, Pages 878-883

  Tripathi, Madhavi ^a   Sharma, Rajnish ^a   D'Souza, Maria ^a   Jaimini, Abhinav ^a   Panwar, Puja ^a   Varshney, Raunak ^a   Datta, Anupama ^a   Kumar, Nitin ^a   Garg, Gunjan ^a   Singh, Dinesh ^a   Grover, Rajesh K ^b   Mishra, Anil K ^a   Mondal, Anupam ^a  

^a INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

^b UCMS AND GTB HOSPITAL   (India)

Author keywords

F 18 FDG; F 18 FLT; F 18 FDOPA; Low grade gliomas; PET CT

Indexed keywords

3' FLUOROTHYMIDINE F 18; 6 FLUORODOPA F 18; AMINO ACID; FLUORODEOXYGLUCOSE F 18; GLUCOSE; TRACER;

ADOLESCENT; ADULT; AMINO ACID METABOLISM; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG SYNTHESIS; DRUG UPTAKE; FEMALE; GLIOMA; GLUCOSE METABOLISM; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MALE; PRESCHOOL CHILD; PROSPECTIVE STUDY; SCHOOL CHILD; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DIDEOXYNUCLEOSIDES; DIHYDROXYPHENYLALANINE; FEMALE; FLUORODEOXYGLUCOSE F18; GLIOMA; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 74249123571     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3181becfe0     Document Type: Article

References (17)

1. Olivero WC, Dulebohn SC, Lister JR. The use of PET in evaluating patients with primary brain tumors: is it useful? J Neurol Neurosurg Psychiatry. 1995;58:250-252.
2. Ricci PE, Daris JP, Heiserman JE, et al. Differentiating recurrent tumor from radiation necrosis time for re-evaluation of positron emission tomography? Am J Neuroradiol. 1998;19:407-413.
3. Ishiwata K, Kutota K, Murakami M, et al. Reevaluation of amino acid PET studies: Can the protein synthesis rates in brain and tumor be measured in vivo? J Nucl Med. 1993;34:1936-1943.
4. Jager PL, Vaalburg W, Pruim J, et al. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med. 2001;42:432-445.
5. Schiepers C, Chen W, Cloughesy T, et al. F-18-FDOPA kinetics in Brain tumors. J Nucl Med. 2007;48:1651-1661.
6. Herholz K, Holzer T, Bauer B, et al. 11C-Methionine PET for differential diagnosis of low-grade gliomas. Neurology. 1998;50:1316-1322.
7. Becherer A, Karanikas G, Szabo M, et al. Brain tumor imaging with PET a comparison between F-18[fluorodopa and 11C]methionine. Eur J Nucl Med Mol Imaging. 2003;30:1561-1567.
8. Chen W, Silverman DH, Delaloye S, et al. F-18 -FDOPA PET imaging of brain tumors: Comparison study with F-18-FDG PET and evaluation of diagnostic accuracy. J Nucl Med. 2006;47:904-911.
9. Shields A, Grierson J, Dohmen B, et al. Imaging proliferation in vivo with F-18- FLT and positron emission tomography. Nat Med. 1998;4:1334-1336.
10. Chen W, Cloughesy T, Kamdar N, et al. Imaging proliferation in brain tumors with F-18-FLT PET: Comparison with F-18-FDG. J Nucl Med. 2005;46:945-952.
11. Rau FC, Weber WA, Wester HJ, et al. O-(2- F-18-Fluroethl)-L-tyrosine (FET): A tracer for differentiation of tumor from inflammation in murine lymph node. Eur J Nucl Med Mol Imaging. 2002;29:1039-1046.
12. Stout DB, Huang SC, Melega WP, et al. Effects of large neutral amino acid concentrations on 6- F-18-fluoro-L-DOPA kinetics. J Cereb Blood Flow Metab. 1998;18:43-51.
13. Kaim AH, Weber B, Kurrer MO, et al. F-18-FDG and F-18-FET uptake in experimental soft tissue infection. Eur J Nucl Med Mol Imaging. 2002;29: 648-654.
14. Yee RE, Cheng DW, Huang SC, et al. Blood brain barrier and neuronal membrane transport of 6- F-18-fluoro-L-DOPA. Biochem Pharmacol. 2001; 62:1409-1415.
15. Padma MV, Said S, Jacobs M, et al. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol. 2003;64:227-237.
16. Rasey JS, Grierson JR, Wiens LW, et al. Validation of FDT uptake as a measure of thymidine Kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43:1210-1217.
17. Sehwartz JL, Grierson JR, Rasey JS, et al. Rates of accumulation retention of 3-deoxy-3-fluorothymidine (FLT) in different cell lines. J Nucl Med. 2001; 42:283-290.